Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Selective iron deposition in the zona glomerulosa of the adrenal cortex is observed in hemochromatosis. Hypoaldosteronism should be excluded before starting venesection, to avoid long-term volume depletion. We evaluated the aldosterone status in patients with hemochromatosis. As other endocrine organs can be affected by the disease as well, we simultaneously evaluated anterior pituitary, gonadal, thyroid and pancreatic beta-cell activity. Nine patients with hereditary or acquired hemochromatosis and highly increased plasma ferritin levels were investigated. In patients, liver cirrhosis had been confirmed histologically. Five patients complained of sexual dysfunction, and one had impaired glucose tolerance. Plasma aldosterone (PA) and renin activity (PRA) were measured after a period of normal (100 mmol/day) and low (10 mmol/day) sodium intake. A combined anterior pituitary function test and a glucagon stimulation test were undertaken to evaluate other endocrine functions. Both PA and PRA levels were decreased in one patient with liver cirrhosis, who also presented attenuated cortisol, prolactin and gonadotrophin secretion. No patients had signs of primary hypoaldosteronism with hyperreninemia. Hypogonadotropic hypogonadism was observed in 3 males and 1 female. Pituitary ACTH reserve was impaired in 2, GH and prolactin response in 1, and thyroid function in none of the patients. Glucagon-stimulated plasma C-peptide was impaired in one patient. In conclusion, primary aldosterone deficiency was not observed in patients with severe iron overload. Hyporeninemic hypoaldosteronism was found in one patient who also presented other endocrinopathies. Hypogonadotropic hypogonadism is the most frequent endocrine abnormality in hemochromatosis.
 ...
PMID:Mineralocorticoid status and endocrine dysfunction in severe hemochromatosis. 1040 11

This investigation was made to assess the effect of iron overload on function of pancreatic islet cells in Wistar rats. Sixty-five male rats were randomly divided into four groups: Group A received repeated intraperitoneal (i. p.) injections of ferric nitrilotriacetate (FeNTA); Group B received the equivalent dose of Na2 NTA; Group C received i. p. injection of Diethylenetriaminepentaacetic acid in addition to FeNTA; and Group D rats were untreated controls. Glucose tolerance tests were performed at the beginning, 5th week, and 10th week. Serum iron(SI) and serum ferritin (SF) were measured. The pancreatic tissues were taken for immunohistochemical exam; the levels of Insulin, Glucagon, ss in islets were also evaluated. At the 10th week, the levels of plasma glucose at 2 hours after glucose load in groups A and C were higher than those in groups B and D (P = 0.043); the granules of insulin in beta cells of group A were decreased obviously, the area of islets of group A was smaller than those of other groups (P = 0. 000). Iron overload might influence glycometabolism. And the beta cells' capability to secrete insulin was decreased obviously. Therefore, by way of removing iron, it is possible to protect the rat's glycometabolism to some extent.
 ...
PMID:[Effect of iron overload on function of pancreatic beta cells in rats]. 1994 96

Glucagon-like peptide-1 (GLP-1) is an incretin (a type of metabolic hormone that stimulates a decrease in blood glucose levels), holding great potential for the treatment of type 2 diabetes mellitus (T2DM). However, its extremely short half-life of 1-2 min hampers any direct clinical application. Here, we describe the application of the heavy chain of human ferritin (HFt) nanocage as a carrier to improve the pharmacological properties of GLP-1. The GLP-HFt was designed by genetic fusion of GLP-1 to the N-terminus of HFt and was expressed in inclusion bodies in E. coli. The refolding process was developed to obtain a soluble GLP-HFt protein. The biophysical properties determined by size-exclusion chromatography (SEC), dynamic light scattering (DLS), circular dichroism (CD), transmission electron microscopy (TEM), and X-ray crystallography verified that the GLP-HFt successfully formed a 24-mer nanocage with GLP-1 displayed on the external surface of HFt. The in vivo pharmacodynamic results demonstrated that the GLP-HFt nanocage retained the bioactivity of natural GLP-1, significantly reduced the blood glucose levels for at least 24 h in a dose-dependent manner, and inhibited food intake for at least 8-10 h. The half-life of the GLP-HFt nanocage was approximately 52 h in mice after subcutaneous injection. The prolonged half-life and sustained control of blood glucose levels indicate that the GLP-HFt nanocage can be further developed for the treatment of T2DM. Meanwhile, the HFt nanocage proves its great potential as a universal carrier that improves the pharmacodynamic and pharmacokinetic properties of a wide range of therapeutic peptides and proteins.
 ...
PMID:Ferritin-Displayed GLP-1 with Improved Pharmacological Activities and Pharmacokinetics. 3224 77